Phillip G. Claringbold

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

Phillip G. Claringbold, Paul Brayshaw, R. Arlen Price et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2010 · 209 citations

Medicine, Oncology, Pharmacology +16

Phase I-II Study of Radiopeptide ¹⁷⁷ Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

Phillip G. Claringbold, R. Arlen Price, J. Harvey Turner · Cancer Biotherapy and Radiopharmaceuticals · 2012 · 163 citations

Medicine, Oncology, Pharmacology +17

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate

Jennifer Turner, Phillip G. Claringbold · European Journal of Cancer and Clinical Oncology · 1991 · 114 citations

Medicine, Oncology, Radiation Oncology +15

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination <sup>177</sup>Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

Phillip G. Claringbold, J. Harvey Turner · Neuroendocrinology · 2015 · 108 citations

Medicine, Oncology, Pharmacology +15

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Phillip G. Claringbold, J. Harvey Turner · Cancer Biotherapy and Radiopharmaceuticals · 2015 · 96 citations

Medicine, Nuclear Medicine, Oncology +17